Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)

2,180 +0,030 (+1,40%) Al cierre: 04:08PM HKT

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Zhangjiang Hi-Tech Park
No. 308 Cailun Road Pudong
Shanghai 201210
China
86 21 5895 3355
https://www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 948

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Da Jun Zhao	Co-Founder, GM & Chairman	N/A	N/A	1970
Mr. Jun Li	Co-Founder & Deputy GM	N/A	N/A	1968
Ms. Xue Yan ACCA, CIA, CICPA, FCCA, HKICPA	CFO, Deputy GM, Company Secretary & Director	N/A	N/A	1982
Mr. Yu Chen	Deputy General Manager	N/A	N/A	N/A
Ms. Xiaowen Li	Deputy General Manager	N/A	N/A	N/A

Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en HKD.

Descripción

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in phase I clinical trials for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

Gobierno corporativo

El ISS Governance QualityScore de Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.